| 1 |
NCT03087370 |
Not yet recruiting |
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Incidence of infections
- Severity of infections
- Incidence of warts
- (and 7 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03087370 |
X4-WHIM-NTHX |
|
March 2017 |
March 2022 |
March 2022 |
March 22, 2017 |
March 28, 2017 |
|
|
| 2 |
NCT03005327 |
Recruiting |
A Trial of X4P-001 in Patients With WHIM Syndrome |
|
- Drug: X4P-001
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events (safety and tolerability)
- Absolute Neutrophil Counts (ANC) over time and/or
- Absolute Lymphocyte Counts (ALC) over time.
- (and 6 more...)
|
42 |
All |
13 Years and older (Child, Adult, Senior) |
NCT03005327 |
X4P-001-MKKA |
X4P-001-MKKA |
December 2016 |
May 2019 |
August 2019 |
December 29, 2016 |
January 10, 2018 |
|
- University of South Florida
Saint Petersburg, Florida, United States - University of Michigan
Ann Arbor, Michigan, United States - University of Washingington Medical Center
Seattle, Washington, United States - St. Vincent's Hospital
Fitzroy, Victoria, Australia
|
| 3 |
NCT00967785 |
Recruiting |
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS |
- WHIMS
- Neutrophil Disorder
- Myelokathexis
- Hypogammaglobulinemia
|
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine whether or not Mozobil (TM) is safe in study population.
- Whether or not treatment results in increased ANC.
|
20 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00967785 |
090200
09-I-0200 |
|
August 4, 2009 |
June 1, 2019 |
December 31, 2019 |
August 28, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT02231879 |
Recruiting |
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome |
- Myelokathexis
- WHIMS
- Neutropenia
- Warts
|
- Drug: Plerixafor
- Drug: G-CSF
|
Interventional |
Phase 3 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The primary endpoint is infection severity, which is measured as a composite of multiple weighted parameters according to rules defined in Appendix D of the protocol.
- Component measures of infections; incidence and duration of infections, fevers, antibiotic treatments, and hospitalization.
- Control of warts as defined by at least a 50% reduction in numbers, areas or size of existing warts and number of new warts.
- Blood count and immunological parameters.
|
30 |
All |
10 Years to 75 Years (Child, Adult, Senior) |
NCT02231879 |
140185
14-I-0185 |
|
September 3, 2014 |
September 30, 2020 |
March 31, 2021 |
September 4, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 5 |
NCT00739869 |
Completed |
Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study) |
|
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- Wake Forest University Health Sciences
|
NIH / Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Prevalence of silent infarcts in women assigned to HRT versus women assigned to placebo
|
1426 |
Female |
65 Years and older (Adult, Senior) |
NCT00739869 |
571
N01-WH-4-4221 |
WHIMS-MRI |
May 2004 |
April 2006 |
March 2007 |
August 22, 2008 |
October 19, 2015 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 6 |
NCT01905475 |
Completed |
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI) |
- Large Reperfused ST-Elevation Myocardial Infarction
|
- Drug: POL6326
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in LVEF (left ventricular ejection fraction) as determined by MRI
- Additional measures of cardiovascular function
- Mobilization of stem and progenitor cells
- (and 2 more...)
|
120 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01905475 |
POL6326-POL-006 |
CATCH-AMI |
July 2013 |
October 2015 |
June 2016 |
July 23, 2013 |
June 10, 2016 |
|
- Medical University of Graz
Graz, Austria - Medical University of Vienna
Vienna, Austria - Kerckhoff-Klinik GmbH
Bad Nauheim, Germany - (and 14 more...)
|
| 7 |
NCT02115672 |
Withdrawn |
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the safety and tolerability of BL-8040 in combination with Imatinib in CML patients
- To assess the clinical efficacy of BL-8040 in combination with Imatinib
|
0 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02115672 |
SHEBA-13-0575-AN-CTIL |
|
November 2014 |
November 2016 |
November 2018 |
April 16, 2014 |
August 15, 2016 |
|
- Chaim Sheba Medical Center
Tel-Hashomer, Israel
|
| 8 |
NCT02069080 |
Suspended |
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor |
|
|
Interventional |
Early Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Lombardi Comprehensive Cancer Center
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Uptake of 64Cu-plerixafor in the target lesion(s) of subjects expressing CXCR4 versus the uptake of 64Cu-plerixafor in the surrounding non-tumor tissues.
- 64Cu-plerixafor SUV in the target lesion(s) versus the level of CXCR4 expression detected via immunohistochemical staining.
- Human-absorbed doses of 64Cu-plerixafor
- The incidence and severity of adverse events (AEs) by dose group.
|
2 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02069080 |
140050
14-I-0050 |
|
February 20, 2014 |
October 31, 2018 |
October 31, 2018 |
February 21, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 9 |
NCT01010880 |
Completed |
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- White blood cell (WBC) count
- CD34+ cells
|
16 |
All |
16 Years to 65 Years (Child, Adult) |
NCT01010880 |
BKTSC001 |
|
October 2008 |
July 2010 |
July 2010 |
November 10, 2009 |
June 10, 2011 |
|
- Department of Hematology and Bone Marrow Transplantation,Rambam Medical Center
Haifa, Israel - Chaim Sheba Medical Center,Tel-Hashomer
Ramat Gan, Israel
|
| 10 |
NCT03436342 |
Not yet recruiting |
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma |
|
|
Interventional |
Early Phase 1 |
- Peking Union Medical College Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- SUVmax
- Diagnostic value
- Incidence of emergency events during the study
- (and 6 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03436342 |
PekingUMCHCXCR4 |
|
May 1, 2018 |
March 1, 2020 |
December 1, 2020 |
February 16, 2018 |
March 20, 2018 |
|
- Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science
Beijing, China
|
| 11 |
NCT03020524 |
Recruiting |
Autologous CD4 T-Cells in HIV (C34-CXCR4) |
|
- Biological: Autologous CD4 T-Cells
|
Interventional |
Early Phase 1 |
- University of Pennsylvania
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The number of subjects with treatment related adverse events
- Compare the percentage of enriched modified cells C34-CXCR4 modifiec T- cells
- Compare the change between CD4 count
- (and 2 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT03020524 |
826035 |
|
January 2017 |
January 2018 |
June 2018 |
January 13, 2017 |
February 8, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 12 |
NCT03225716 |
Recruiting |
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia |
- Waldenstrom's Macroglobulinemia
|
- Drug: Ulocuplumab
- Drug: Ibrutinib
|
Interventional |
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of Ulocuplumab
- Major Response Rate
- Time to Minor Response
- (and 3 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT03225716 |
17-235 |
|
October 20, 2017 |
January 31, 2021 |
January 31, 2025 |
July 21, 2017 |
April 6, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 13 |
NCT00685009 |
Completed |
The Women's Health Initiative Memory Study (The WHIMS Study) |
|
- Drug: Estrogen hormone therapy
- Drug: Estrogen plus progesterone hormone therapy
- Drug: Placebo
|
Observational |
|
- National Heart, Lung, and Blood Institute (NHLBI)
- Wake Forest University Health Sciences
|
NIH / Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- All-cause dementia
- Mild cognitive impairment
|
7525 |
Female |
65 Years to 79 Years (Adult, Senior) |
NCT00685009 |
548
N01-WH44221 |
|
January 1996 |
September 1997 |
March 2008 |
May 28, 2008 |
October 19, 2015 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 14 |
NCT01236144 |
Completed |
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. |
- Acute Myeloid Leukaemia
- High Risk Myelodysplastic Syndrome
|
- Drug: Plerixafor
- Drug: AC220
- Drug: Ganetespib
|
Interventional |
Phase 1
Phase 2 |
- Cardiff University
- Leukaemia & Lymphoma Research Group
- Experimental Cancer Medicine Centre Network
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response (CR, CRi, PR) achievement, and reasons for failure
- Mortality
- Toxicity (haematological and non-haematological)
- Survival
|
113 |
All |
60 Years and older (Adult, Senior) |
NCT01236144 |
SPON 845-10
2010-021444-18
10/MRE09/27 |
AML18 Pilot |
April 2011 |
December 2013 |
January 2014 |
November 8, 2010 |
June 11, 2014 |
|
- Aberdeen Royal Infirmary
Aberdeen, United Kingdom - Belfast City Hospital
Belfast, United Kingdom - Birmingham Heartlands Hospital
Birmingham, United Kingdom - (and 10 more...)
|
| 15 |
NCT01295242 |
Completed |
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) |
- Papillomavirus Infections
|
|
Observational |
|
|
Other |
- Time Perspective: Prospective
|
- Presence of type-specific HPV DNA in self-collected oral and vaginal swab samples
|
409 |
Female |
30 Years to 50 Years (Adult) |
NCT01295242 |
39810-C |
WHIM |
February 2011 |
August 2012 |
August 2012 |
February 14, 2011 |
November 19, 2013 |
|
- University of Washington
Seattle, Washington, United States
|
| 16 |
NCT00745056 |
Active, not recruiting |
Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study) |
|
|
Observational |
|
- Wake Forest University Health Sciences
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- All-cause dementia and Mild Cognitive Impairment
- Global and domain specific cognitive function
|
2922 |
Female |
65 Years and older (Adult, Senior) |
NCT00745056 |
1436 |
WHIMS-ECHO |
August 2008 |
November 2021 |
November 2021 |
September 1, 2008 |
November 6, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 17 |
NCT00173849 |
Unknown † |
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma |
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Allocation: Random Sample
- Observational Model: Natural History
- Time Perspective: Longitudinal
- Time Perspective: Retrospective/Prospective
|
|
100 |
All |
30 Years to 75 Years (Adult, Senior) |
NCT00173849 |
9461700656 |
|
January 2006 |
|
July 2006 |
September 15, 2005 |
September 15, 2005 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 18 |
NCT01072734 |
Completed |
Auto-immunity in Lupus Patients After Influenza Vaccine |
- Systemic Lupus Erythematosus (SLE)
|
|
Interventional |
Phase 2 |
- Assistance Publique - Hôpitaux de Paris
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The expression of CXCR4 on B cells, T cells, monocytes and granulocytes by FACS on LES patients will be measured the day of the vaccination and then 7 and 30 days post-vaccination
- The biological signs of autoimmunity will be followed using the routine laboratory tests such as the complement exploration and the detection of total anti-nuclear antibodies detection
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT01072734 |
P090104 |
GRIPLUP |
September 2009 |
January 2010 |
February 2010 |
February 22, 2010 |
October 13, 2010 |
|
- CIC Vaccinologie Hopital Cochin
Paris, France
|
| 19 |
NCT01686685 |
Completed |
Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months |
- Autism Spectrum Disorder
- Complication of Prematurity
|
|
Observational |
|
- Hadassah Medical Organization
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Diagnosis of ASD at 24 months corrected age
- Language or cognitive delay at 24 months corrected age
|
400 |
All |
up to 1 Day (Child) |
NCT01686685 |
begin1HMO-CTIL |
ASD-CXCR4 |
September 2013 |
April 2018 |
April 1, 2018 |
September 18, 2012 |
April 12, 2018 |
|
- Hadassah Medical Center
Jerusalem, Israel
|
| 20 |
NCT00174096 |
Unknown † |
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
- Laryngeal Cancer
- Hypopharyngeal Cancer
- Metastasis
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Allocation: Random Sample
- Observational Model: Natural History
- Time Perspective: Longitudinal
- Time Perspective: Retrospective
|
|
100 |
All |
30 Years to 75 Years (Adult, Senior) |
NCT00174096 |
9461700624 |
|
August 2005 |
|
July 2006 |
September 15, 2005 |
March 31, 2006 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 21 |
NCT00089466 |
Completed |
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients |
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- AIDS Clinical Trials Group
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicities of Grade 3 or greater
- Reduction in X4-tropic virus from baseline of 1 log10 relative luciferase units (rlu)
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT00089466 |
A5210
10020
ACTG A5210 |
|
November 2004 |
June 2006 |
January 2009 |
August 6, 2004 |
October 31, 2012 |
|
- Alabama Therapeutics CRS
Birmingham, Alabama, United States - The Ponce de Leon Ctr. CRS
Atlanta, Georgia, United States - Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana, United States
|
| 22 |
NCT01058993 |
Completed
Has Results |
AMD 3100 for Treatment of Myelokathexis |
|
- Drug: AMD3100 or plerixafor
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT01058993 |
35419-D
MAMO-0407-1 |
|
October 2010 |
March 2011 |
April 2011 |
January 29, 2010 |
June 15, 2012 |
June 15, 2012 |
- University of Washington Medical Center
Seattle, Washington, United States
|
| 23 |
NCT01374503 |
Terminated |
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4 |
|
- Biological: ALX-0651
- Biological: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Number of treatment emergent adverse events
- maximum plasma concentration (Cmax) of ALX-0651
- CD34 positive cell count in blood
|
52 |
Male |
18 Years to 55 Years (Adult) |
NCT01374503 |
ALX-0651-1.1/11 |
|
June 2011 |
January 2012 |
January 2012 |
June 16, 2011 |
April 17, 2012 |
|
|
| 24 |
NCT01359657 |
Completed |
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma |
|
- Biological: Anti-CXCR4 (BMS-936564)
- Biological: Lenalidomide
- Biological: Dexamethasone
- Biological: Bortezomib
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of maximum tolerated dose
- Safety and tolerability will be analyzed for all patients. Safety endpoints will be based on adverse event reports, and include frequent adverse event (AE)s, serious adverse event (SAE)s and lab abnormalities
- Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be maximum observed concentration (Cmax)
- (and 12 more...)
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT01359657 |
CA212-002 |
|
September 2011 |
March 2016 |
March 2016 |
May 25, 2011 |
March 16, 2016 |
|
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States - University Of Kansas Cancer Center And Medical Pavillion
Westwood, Kansas, United States - Dana Faber Cancer Institute
Boston, Massachusetts, United States - University Of Washington School Of Medicine
Seattle, Washington, United States
|
| 25 |
NCT00155844 |
Unknown † |
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" |
- Acute Myelocytic Leukemia
- Acute Lymphocytic Leukemia
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case Control
- Primary Purpose: Screening
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
30 |
All |
Child, Adult, Senior |
NCT00155844 |
9200200606 |
|
February 2003 |
|
July 2004 |
September 12, 2005 |
September 12, 2005 |
|
- Liang-In Lin
Taipei, Taiwan
|
| 26 |
NCT01120457 |
Completed |
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers |
- Acute Myelogenous Leukemia
- Diffuse Large B-Cell Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
|
- Drug: BMS-936564 (Anti-CXCR4)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability as monotherapy
- Safety, as measured by vital signs, clinical laboratory tests,ECOG performance status, physical exams, 12 lead ECGs incidence and severity of adverse events
- Efficacy- including best overall response (BOR) derived from changes in tumor burden and metabolic response based on FDG-PET (for DLBCL)
- (and 12 more...)
|
96 |
All |
18 Years and older (Adult, Senior) |
NCT01120457 |
CA212-001 |
|
August 2010 |
November 2014 |
November 2014 |
May 11, 2010 |
March 6, 2015 |
|
- Uab Comprehensive Cancer Center
Birmingham, Alabama, United States - Uc San Diego Moores Cancer Center
La Jolla, California, United States - Usc - Norris Comprehensive Cancer Center And Hospital
Los Angeles, California, United States - (and 8 more...)
|
| 27 |
NCT02605460 |
Recruiting |
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission |
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
|
- Drug: Busulfan
- Drug: Cyclophosphamide
- Drug: CXCR4 Antagonist
- Procedure: Hematopoietic Stem Cell Transplantation
|
Interventional |
Phase 2 |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Disease Free Survival
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT02605460 |
INCMNSZ REF 917 |
|
February 2014 |
June 2018 |
December 2018 |
November 16, 2015 |
November 13, 2017 |
|
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Distrito Federal, Mexico
|
| 28 |
NCT01272674 |
Completed |
Adiponectin and Circulating Progenitor Cells (CPC) Function |
|
|
Interventional |
Phase 1 |
- University of Leipzig
- German Research Foundation
- Heartcenter Leipzig GmbH
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- migratory capacity of endothelial progenitor cells towards an SDF-1 gradient
|
20 |
Male |
18 Years to 75 Years (Adult, Senior) |
NCT01272674 |
adipo2008 |
|
January 2011 |
March 2011 |
March 2011 |
January 10, 2011 |
June 2, 2015 |
|
- University of Leipzig, Heart Center
Leipzig, Germany
|
| 29 |
NCT02737072 |
Terminated |
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors |
|
- Drug: LY2510924
- Drug: Durvalumab
|
Interventional |
Phase 1 |
- Eli Lilly and Company
- AstraZeneca
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
- Maximum Tolerated Dose (MTD) of LY2510924
- Pharmacokinetics: Area Under the Concentration-Time Curve (AUC0-24) of LY2510924 when Co-Administered with Durvalumab
- (and 3 more...)
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT02737072 |
16387
I2V-MC-CXAD |
|
September 2016 |
September 2017 |
September 2017 |
April 13, 2016 |
November 17, 2017 |
|
|
| 30 |
NCT00321438 |
Terminated |
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus |
|
|
Observational |
|
|
Industry |
- Time Perspective: Prospective
|
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT00321438 |
CCR104629 |
|
July 2005 |
|
|
May 3, 2006 |
May 18, 2009 |
|
- GSK Investigational Site
Los Angeles, California, United States - GSK Investigational Site
Tarzana, California, United States - GSK Investigational Site
Washington, District of Columbia, United States - (and 12 more...)
|
| 31 |
NCT03277209 |
Recruiting |
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas |
|
|
Interventional |
Phase 1 |
- Weill Medical College of Cornell University
- Cambridge University Hospitals NHS Foundation Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Causality of adverse events (AEs) and serious adverse events (SAEs) and grading according to NCI CTCAE v.4.03.
- Assessment of metabolic changes in tumour using non-invasive imaging (18FDG-PET)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT03277209 |
1508016466 |
|
July 25, 2017 |
December 2019 |
December 2020 |
September 8, 2017 |
September 8, 2017 |
|
- Weill Cornell Medical College
New York, New York, United States - Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
|
| 32 |
NCT02179970 |
Recruiting |
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers |
- Pancreatic Adenocarcinoma Metastatic
- Ovarian Serous Adenocarcinoma
- Colorectal Cancer Metastatic
|
|
Interventional |
Phase 1 |
- CCTU- Cancer Theme
- Sanofi
- Stand Up To Cancer
- (and 4 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
28 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02179970 |
CAM-PLEX
2014-000117-31 |
CAM-PLEX |
June 2015 |
March 2018 |
June 2018 |
July 2, 2014 |
January 9, 2018 |
|
- Addenbrookes Hospital
Cambridge, United Kingdom
|
| 33 |
NCT00512252 |
Completed
Has Results |
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia |
|
- Drug: AMD3100
- Drug: Mitoxantrone
- Drug: Etoposide
- Drug: Cytarabine
|
Interventional |
Phase 1
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML
- Phase II Only: Complete Response Rate of AMD3100 + MEC
- Ability of AMD3100 + MEC to Induce dsDNA Damage and Apoptosis in Leukemic Blasts From Bone Marrow or Peripheral Blood Fractions
- (and 10 more...)
|
52 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00512252 |
07-0227 / 201011796 |
AMD3100+MEC |
July 2007 |
June 2010 |
June 2010 |
August 7, 2007 |
December 12, 2016 |
September 22, 2014 |
- Washington University
St. Louis, Missouri, United States
|
| 34 |
NCT00063804 |
Completed |
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men |
|
- Drug: Ritonavir
- Drug: AMD070
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- AIDS Clinical Trials Group
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- AMD070 pharmacokinetic (PK) parameters under three conditions, and the within-volunteer differences between them
- Steady-state RTV PK parameters
- Grade 3 and 4 adverse effects, as defined by the protocol
|
44 |
Male |
18 Years to 55 Years (Adult) |
NCT00063804 |
A5191
10012
ACTG A5191 |
|
|
|
October 2006 |
July 8, 2003 |
May 21, 2012 |
|
- Johns Hopkins Adult AIDS CRS
Baltimore, Maryland, United States - University of Washington AIDS CRS
Seattle, Washington, United States
|
| 35 |
NCT03335670 |
Recruiting |
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Early Phase 1 |
- Yusuf Menda
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Determine biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor in patients with neuroendocrine tumors (NETs)
- Determine the repeatability of [68Ga]Pentixafor uptake in known neuroendocrine tumor lesions
- Compare standardized uptake values of [68Ga]Pentixafor and [68Ga]DOTATATE in known neuroendocrine tumor lesions
- Correlate the uptake of [68Ga]Pentixafor and [68Ga]DOTATATE (NetSpot) in known neuroendocrine tumor lesions with expression of receptors (CXCR4 and SSTR2) in biopsy tissue samples.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03335670 |
201708705
P50CA174521 |
|
November 3, 2017 |
October 1, 2019 |
December 31, 2020 |
November 8, 2017 |
January 9, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
| 36 |
NCT01841476 |
Completed |
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of single ascending doses of POL6326 by intravenous infusion according to standard criteria
- Pharmacokinetic outcome
- Mobilisation of CD34+ cells
|
27 |
Male |
18 Years to 55 Years (Adult) |
NCT01841476 |
POL-3 |
|
February 2012 |
August 2015 |
September 2015 |
April 26, 2013 |
November 25, 2015 |
|
- German Red Cross Blood Service and Institute for Transfusion Medicine and Immunohematology of the Goethe University
Frankfurt, Germany
|
| 37 |
NCT00906945 |
Completed
Has Results |
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia |
|
- Drug: G-CSF
- Drug: Plerixafor
- Drug: Mitoxantrone
- (and 2 more...)
|
Interventional |
Phase 1
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Maximum Tolerated Dose of Plerixafor Plus G-CSF When Combined With MEC
- Phase II: Complete Response Rate (CR+CRi)
- Phase I and Phase II: Safety and Tolerability of Regimen as Measured by Grade and Frequency of Adverse Events Exceeding 10% in Total Frequency
- (and 9 more...)
|
39 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00906945 |
10-0910 / 201106039 |
|
February 2011 |
November 2012 |
September 2015 |
May 21, 2009 |
April 4, 2017 |
April 4, 2017 |
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Washington University
St. Louis, Missouri, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
| 38 |
NCT00733824 |
Completed
Has Results |
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma |
- Lymphoma, Non-Hodgkin
- Hodgkin Disease
|
- Drug: AMD3100
- Drug: G-CSF
- Procedure: Apheresis
|
Interventional |
Phase 1
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of IV AMD3100 + G-CSF in Mobilization of Peripheral Blood Stem Cell in Patients With Lymphoma (Phase I Only)
- Number of Participants Who Experienced Dose Limiting Toxicities in Phase I Portion of Study
- Kinetics of Stem Cell Mobilization Using IV AMD3100 as Measured by Median Fold Change in the Number of CD34+ Cells After AMD3100 IV Administration
- (and 2 more...)
|
61 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00733824 |
08-0897 / 201105349 |
|
November 2008 |
September 2012 |
September 2013 |
August 13, 2008 |
March 9, 2017 |
October 28, 2016 |
- Washington University School of Medicine
St. Louis, Missouri, United States
|
| 39 |
NCT00322127 |
Completed |
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers |
|
|
Interventional |
Phase 1 |
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To further assess the safety and tolerability profile of AMD3100 when administered in escalating higher doses (240 microgram/kg dose, 320 microgram/kg dose 400 microgram/kg dose 480 microgram/kg dose) in humans.
- To determine the peak CD34+ cell mobilization kinetics of AMD3100 in successive cohorts of healthy subjects receiving two different doses of AMD3100.
|
44 |
All |
18 Years to 50 Years (Adult) |
NCT00322127 |
060156
06-H-0156 |
|
May 3, 2006 |
January 23, 2015 |
January 23, 2015 |
May 5, 2006 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 40 |
NCT00302562 |
Unknown † |
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
- Laryngeal Cancer
- Hypopharyngeal Cancer
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Allocation: Random Sample
- Observational Model: Natural History
- Time Perspective: Longitudinal
- Time Perspective: Retrospective/Prospective
|
|
100 |
All |
30 Years to 75 Years (Adult, Senior) |
NCT00302562 |
9461701234 |
|
August 2006 |
|
July 2007 |
March 14, 2006 |
March 14, 2006 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 41 |
NCT02765165 |
Active, not recruiting |
Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) |
- Solid Tumors (Phase 1)
- Relapsed/Recurrent GBM (Phase 2)
|
- Drug: USL311
- Drug: Lomustine
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
- Phase 2: Percentage progression free survival (PFS) at 6 months (PFS-6m)
- Phase 1 and Phase 2: Treatment-related adverse events as assessed by CTCAE v4.03
- (and 6 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02765165 |
P311-201 |
|
April 2016 |
December 2019 |
|
May 6, 2016 |
September 12, 2017 |
|
- University of Oklahoma Stephenson Cancer Center
Oklahoma City, Oklahoma, United States - University of Texas/MD Anderson Cancer Center
Houston, Texas, United States - South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States - (and 2 more...)
|
| 42 |
NCT00299897 |
Unknown † |
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients |
- HIV Infections
- Human Immunodeficiency Virus
|
|
Interventional |
Phase 2 |
- Samaritan Pharmaceuticals, Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Within treatment group reduction in viral load (log10) in each SP01A active arm as well as within the placebo arm as measured from DAY-1 (Baseline) to DAY-22, and DAY-29 (Study-End).
- Reduction in viral load compared across SP01A active arms measured from DAY-1 (Baseline) to DAY-22 and DAY-29 (Study-End).
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT00299897 |
SP01A-111-05 |
|
March 2006 |
|
|
March 7, 2006 |
October 27, 2006 |
|
- AIDS Healthcare Foundation
Beverly Hills, California, United States - Therafirst Medical Centers
Fort Lauderdale, Florida, United States - Infectious Disease of Central Florida
Orlando, Florida, United States - (and 2 more...)
|
| 43 |
NCT00082329 |
Completed
Has Results |
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers |
|
- Drug: AMD 3100 (Mozobil plerixafor)
|
Interventional |
Phase 2 |
- Richard Childs, M.D.
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Determine the Cytokine Polarization Status of Cluster of Differentiation 4 (CD4)+ T-cells Collected by Apheresis Following Combination of AMD3100 and G-CSF Compared to G-CSF Mobilization.
- To Examine 1) the Cellular Content and Other Immune Properties of Mobilized Cells; 2) Yields of Hematopoietic Progenitor Cells, Immune Cells, and Other Cellular Subsets Collected by Apheresis; and 3) Safety Profile of AMD3100.
|
9 |
All |
18 Years to 60 Years (Adult) |
NCT00082329 |
040179
04-H-0179 |
|
May 2004 |
October 2012 |
October 2012 |
May 6, 2004 |
May 2, 2014 |
May 2, 2014 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 44 |
NCT00243568 |
Terminated |
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285)(TERMINATED) |
- HIV Infections
- Acquired Immunodeficiency Syndrome
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT00243568 |
P04285
EudraCT number 2005-001058-26 |
|
September 2005 |
|
|
October 24, 2005 |
October 23, 2009 |
|
|
Create an RSS feed from your search for:
Download the search results for: